We propose to construct a realistic statistical model of lung cancer risk and progression. The essential elements of the model are genetic and behavioral determinants of susceptibility, progression of the disease from precursor lesions through early localized tumors to disseminated disease, detection by various modalities, and medical intervention. Using model estimates as a foundation, mortality reduction caused by early-detection and intervention programs can be predicted under different scenarios. Genetic indicators of susceptibility to lung cancer should be utilized to define the highest-risk subgroups of the high-risk behavior population (smokers). Calibration and validation of the model will be done by applying our techniques to a variety of data sets available, including public registry data of the SEER type, data from the NCI lung cancer chest X-ray screening studies, and the recent ELCAP CT-scan screening study.
Introduction
One of the strategies of defeating cancer is to detect it early. The philosophy is simple: The earlier the cancer is detected, the smaller the chance that it already has spread beyond the limited primary focus. This implies that the extent of intervention needed is lesser and the prognosis improved. This philosophy can be translated into a practical program: (1) Identify a population at high risk for a given cancer. (2) Develop an efficient and inexpensive method of early detection of non-symptomatic tumors. (3) Develop a program of periodic examinations (screening) of the high-risk group using the early detection method. (4) Treat the early cancer cases detected in this way. This will reduce mortality from the target cancer. (Fig. 1) Unfortunately, in most common cancers, such as cancers of lung, colon, breast and prostate, the early detection and treatment paradigm works quite poorly. A notable exception is the cancer of uterine cervix, in which a simple early detection method (Pap smears) followed by prompt treatment seems to significantly reduce mortality.
What are the reasons for this failure? As we will see, none of the four steps outlined is easy to implement. Origin and progression of cancer are stochastic and dynamic in nature and so is detection and, to some extent, treatment. Ignoring these features leads to incorrect estimates and predictions and, in some cases, to incorrect policy recommendations.
The talk is a review of statistical and health policy problems related to early detection of cancer using mass screening examinations. We discuss a stochastic model (or models) of progression, detection and treatment of cancer, to put our questions into a rigorous setting. Our considerations will be based on the important example of lung cancer, but they are applicable, with appropriate changes, to other cancers.
A stochastic model of lung cancer involves genetic and behavioral determinants of susceptibility, progression of the disease from precursor lesions through early localized tumors to disseminated disease, detection by various modalities, and medical intervention. The model should be able to predict mortality reduction caused by early-detection programs, under different scenarios, in presence of competing death causes. As mentioned above, it will be important to utilize the genetic indicators of susceptibility to lung cancer to define the highest-risk subgroups of the high-risk behavior population (smokers). Estimation techniques are needed to obtain distributions of the parameters of the model, using simulation and Bayesian hierarchical modeling.
Although the emphasis is on methodology, we will show the performance of the model on a range of data sets available to us, such as data from the NCI lung cancer chest Xray screening studies, the recent ELCAP computed tomography (CT-scan) screening study and some published data.
Background on lung cancer
Lung cancer remains the largest killer among all cancers in the USA and in the world. It kills more people of both genders than cancers of breast, colon and prostate combined, and more women than breast cancer. An overwhelming majority of cases is related to exposure to Polycyclic Aromatic Hydrocarbones (PAH; first of all, in the tobacco smoke) [l] , but the genetic predisposition also plays a major role [21- Two major factors make lung cancer difficult to fight. One of them is that majority of cases are detected only when they are quite advanced. Attempts at early detection using chest X-ray and sputum cytology screening of high-risk individuals produced controversial and ambiguous results [5] -[SI. Another factor is that the high-risk population (cigarette smokers) has largely evaded the attempts at further stratification with respect to their risk of contracting the disease.
There has been a recent progress in lung cancer detection techniques as well as in understanding the genetic factors affecting individual's susceptibility to this disease. Computed tomography (CT) allows visualization of very small nodules in the lungs and therefore it has the potential to detect malignant tumors when they still are in an early stage.
Results of preliminary studies in the United States [9] -[ 1 11, Japan [ 121-[ 131 and Western Europe [ 141-[ 151 have been published and they point at an increased detection rate of potential early malignancies. The probability that these develop into progressing lung cancers is not known, particularly that of some of the lesions (e.g. the so-called "ground glass opacities", or GGO) which frequently lack welldefined nodule components [ 161.
Another area of progress concerns the genetic factors predisposing individuals to developing lung cancer. There exist a lot of data, concerning mostly families of lung cancer patients [2] .
Screening for lung cancer: ideas and biases
As already mentioned, the idea underlying mass-screening programs for early detection of cancer is that a sensitive detection technique (chest X-ray, CT-scan or biomarkers) allows diagnosis of lung cancer in an early stage when it is still curable (Fig. 1) . If the early-stage detection is followed by appropriate treatment, then mass screening can result in a reduction of population mortality attributed to lung cancer.
There exist several caveats, which have to be considered to understand how difficult a practical implementation of this principle can be.
Definition of the high-risk population. If the high-risk population is overly inclusive (e.g. all smokers), the yield of cases in the program will be low. This may reduce our ability to decide if the observed mortality reduction is significant, and it may inflate the cost o€ the program. Attempts should be made to use genetic (and other) parameters to pinpoint the highest-risk group(s).
Screening biases. (i)
The lead-time bias results from the fact that early detection inflates survival estimates even if it does not increase the probability of cure.
(ii) The length bias (overdiagnosis bias) results from the fact that screening is more likely to detect longerlasting and therefore possibly more indolent cases. This bias can inflate cure rates of screen-detected cases, by including indolent cases, which would not surface in the absence of screening [17] . (iii) An opposite effect will be observed if the biology of lung cancer causes it to progress (metastasize) already when the primary nodule is very small. This will make early detection a futile exercise as removal of a small primary will not improve curability [ 181.
Randomized Clinical Trials (RCT).
RCT is a comparison of lung cancer mortalities in a study in which high-risk subjects are randomly assigned to two groups, screened and control. After a predetermined time, the numbers of deaths from lung cancer in both groups are compared. This design removes the impact of lead-time and length biases. However, it is sensitive to noncompliance of screened and contamination of controls by voluntary screening. Also, if the yield of cases is low and I or reduction of mortality is real but less than expected or if it occurs after a time longer than expected, the design may yield inconclusive results [ 191.
Several major RCTs of lung cancer screening were carried out using chest X-ray and sputum cytology as detection tools. None of them demonstrated a reduction in mortality from lung cancer. Increases in the number of early-stage lung cancers in the screening group were observed (and these cases enjoyed a much improved survival), but they were attributed to the lead-time and overdiagnosis biases [7] . These findings resulted in recommendations by the American Cancer Society and National Cancer Institute against annual chest X-ray examinations of smokers' lungs and in generally adverse attitudes towards the potential of screening for lung cancer [20] . Even in view of the recent application of CT-scan as a screening tool, the medical community remains cautious, as evidenced by a number of recent publications [21] .
Simple model of lung cancer
The mathematical model of the natural history of lung cancer in a periodically screened population was previously described [6] , [22] . Here we present the assumptions that capture the essential properties of the progression dynamics of lung cancer.
1. In the high-risk population selected for screening, a subgroup of participants is susceptible to non-small cell lung cancer. The probability that a person belongs to this group is p.
In the absence of screening and treatment, non-small cell lung cancer after its onset progresses through 2 stages -early and advanced -followed by death from cancer.
For a person in the susceptible subgroup, the age of onset of the early stage, T~, is a random variable with a trapezoidal distribution.
The durations of the early and advanced stages, T~ and T~, are independent exponential random variables with means p1 and p2, respectively.
The screening program consists of examinations at fixed intervals intended to detect the cancer.
Those participants whose lung cancers are detected and treated at the first screening (prevalence cases) are removed from the study and control groups.
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Given the presence of early cancer, the first examination after the onset of the disease detects early cancer with probability p. If no detection occurs, each subsequent examination detects the early cancer with probability hp. Since a small tumor missed on one examination because of its location in the chest is likely to escape detection again 4 month later, 3L was assumed less than 1. Detection on successive examinations is independent. It is assumed that advanced cancers are surely detected after the stage transition.
When cancer is detected, screening is aborted and the patient is treated. The probability of cure of early-stage lung cancer is equal to c; there is no possibility of cure in advanced-stage lung cancer. Cure is defined pragmatically in terms of the survival of patients after detection: if patients are cured, their ages at death are the same as if they had never had cancer; if they are not cured, their ages at death are the same as if their cancer had not been detected through screening.
Distribution of ages at enrollment and death from competing causes are estimated from the data.
The model is among the simplest imaginable. It can be run using simulation, but a range of analytic techniques was also developed. It explains the reasons for the failure to observe a reduction of mortality in X-ray-based screening programs and provides predictions of improved efficacy of screening techniques such as CT-scan.
The model shows that the duration of screening in an RCT is very important (Fig. 2) , particularly when the effect of screening is around 20% as presumed for chest radiogra-8. 9 . phy, thus much less than that for CT
Modeling stochastic transitions in lung cancer
A more refined model of progression of cancer should include several mechanisms, which recently became estimable due to an influx of new data:
Genetic determinants of carcinogenesis. Lung cancer is caused by accumulation of DNA defects caused by exposition to PAH metabolites. PAH are metabolized by a cascade of reactions facilitated by enzymes, expresses differently in different individuals. Considering genetic susceptibility to PAH-induced DNA demages will help isolating the highest-risk subpopulation.
Models of tumor growth. Repeated measurements of very small tumors obtained from CT-scans will allow estimation of variability in the rate and pattem of growth of early lung cancer Ell]. These estimates can be obtained using maximum likelihood and imputation methods, whenever measurements are missing or biased.
Models of tumor-size dependent metastases. Stochastic modeling allows integrating data from different sources (CT-scan and X-ray screening programs and clinicalcase registries) representing samples of tumors of different age. Therefore it is possible to estimate the probabilities of lymph node and distant organ metastasis for tumors of different sizes (cell type, molecular features, and so forth). Techniques, using the E-M algorithm, have been already developed [23] .
Recently we developed a method to estimate the population variability in tumor growth rate using data from screening programs. We apply a maximum likelihood approach if two size measurements of a tumor at two different time points are available. We assume the exponential law of growth, so that
where s is size (volume in our case), t is time, r is a parameter characterizing growth rate. We suppose that r is lognormally distributed random variable; consequently, lnr is distributed normally with parameters ( p , T 2 ) . We develop a procedure to estimate these parameters by maximum likelihood to show that f i = n If two measurements are available for some tumors and only one measurement for others (which means that no tumor was seen in retrospect for those cases), then a semisimulation approach was used. The idea of the latter was to reconstruct the missing measurement as being below the detection threshold. The threshold is considered a lognormal random variable, distribution of which can be, with some approximation, estimated from data.
First, the maximum likelihood estimates for p and T were obtained based only on cases with 2 measurements, as described above. These estimates were then used as initial values in the procedure as follows: A lognormal random variable r (growth rate) was generated with p and Z so specified. Then the threshold value was generated from the lognormal distribution with corresponding parameters (median and 90% quantile estimated as 12 mrn and 43 mm in diameter). Based on the equation of exponential growth, generated value of r, a known tumor size at detection and the time interval between detection (t2) and previous examination (tl) with the negative result, a tumor size SI at the time of the previous examination (tl) was calculated. If the size happened to be greater than the threshold, r was generated anew until the tumor at tl became less than the threshold. The procedure was performed for every case for which only one measurement was available. As a result, "missing" tumor sizes at tl were restored for 1-measurement cases. For this partially simulated data set, maximum likelihood estimate for p and T 2 was recalculated. The procedure was repeated 30 times and then the final estimates are obtained by averaging over the all iterations. The procedure was verified by simulating data for a range of initial parameters p and T 2 and several sets of detection threshold distributions. For convenience, the tumor volume doubling time Td (in days) was used along with growth rate. The relationship between these two parameters is as follows, The distribution of the doubling times was compared to the actual distribution of log growth rates, which was known from simulation. The comparison was based on a numerical approximation of the following index and where F-' (U) and F'il (U) are the inverse cumulative distribution fimctions of the estimated doubling times and of the simulated doubling times, respectively, divided by the median doubling time in the simulations. The index can be interpreted as a standardized mean of absolute differences between the estimated and simulated doubling times. Without getting into details, the relative error index Z rarely exceeds 0.15 -0.20.
cluded, and thus most fast growing tumors are disregarded. Prospective re-examination does not eliminate any of possible fast growing tumors. Concluding, each set of the data will be intrinsically characterized by a different distribution of growth rates or, equivalently, doubling times. The results of application of our estimation procedures to the MSKCC chest X-ray screening data agree well with the expectations (Table 1) . We then applied our procedures to several data sets that 6 Conclusions originated fi-om different studies (Gorlova et al., in preparation). The estimates obtained based on measurements from different studies vary widely (Table l) , which is not surprising in view of different ways in which these samples were ascertained. When the sensitivity of screening is low (as in chest X-ray detection of lung cancer), screen-detected cases represent mainly slowly growing tumors. This effect is caused in part by the length bias [17] . If the sensitivity is high, we can expect to find very small tumors, which are not necessarily growing slowly. As to interval cases detected between chest X-ray screens, in many cases they represent tumors growing fast so that they are too small to be detected at the previous examination but reach detectable size or become symptomatic before the next screen. Using
Integration of detailed estimates of stochastic transitions into the progression network of lung cancer with screening detection and subsequent treatment will make it possible to predict efficacy of different detection programs. It will also allow optimizing the selection of individuals to be included in mass screening. It is the only method, which allows accomplishing these tasks in the presence of continuous change in detection and treatment techniques as well as in presence of varying exposure to carcinogens (fluctuating with behavioral factors such as smoking) and differing genetic makeup of people at risk.
